Application of protein in preparation of medicine for preventing and treating atherosclerosis and complications

A technology for atherosclerosis and atherosclerosis, which is applied in the field of biomedicine, can solve the problems of limited research level and no drugs for oxLDL clearance, and achieve the effect of reducing the ratio level.

Pending Publication Date: 2020-03-17
SHANGHAI CLEAR FLUID BIOMEDICAL SCI CO LTD
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

oxLDL is a key factor affecting the process of atherosclerosis, but limited by the current research level, most treatments targeting oxLDL are at the level of basic research
According to literature research, 3 oxLDL antibodies have applied for patents (patent numbers: U

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of protein in preparation of medicine for preventing and treating atherosclerosis and complications
  • Application of protein in preparation of medicine for preventing and treating atherosclerosis and complications
  • Application of protein in preparation of medicine for preventing and treating atherosclerosis and complications

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0114] Example 1. sDSS1 protein can interact with oxLDL or LDL.

[0115] 1.1 Experimental materials and methods

[0116] Experimental materials: sDSS1 protein, oxidized low-density lipoprotein (oxLDL) (Solebo, product number: H7980); low-density lipoprotein (LDL) (Solebo, product number: H7960).

[0117] Experimental method: 2μg of oxLDL or LDL and 6μg of sDSS1 protein or 10μg of sDSS1 protein were added to 1.5ml under the condition of 20mM sodium acetate / acetate buffer (pH4.5) or 20mM phosphate buffer (pH7.2), respectively. Mix in EP tubes and incubate at 37 °C for 12 h. The incubation product was added with loading buffer and mixed, and denatured at 100°C for 10 minutes to prepare a loading sample. The prepared samples were separated by polyacrylamide gel electrophoresis (SDS-PAGE). After separation, the SDS-PAGE gel was stained with Coomassie brilliant blue to reveal protein bands.

[0118] 1.2 Experimental results

[0119] In the acetate buffer system (pH 4.5), LDL pro...

Example Embodiment

[0122] Example 2. sDSS1 protein can reduce the uptake of oxLDL by vascular endothelial cells.

[0123] 2.1 Experimental materials and methods

[0124]Experimental materials: sDSS1 protein, Dil-oxLDL (Thermo Fisher Scientific, product number: L34358), human umbilical vein endothelial cells (HUVEC) (PromoCell, product number: C-12200)

[0125] Experimental method: HUVEC cells were seeded into 6-well plates according to the cell number of 300,000 per well. After 24 hours of adherence, 1.5ml of 10μg / ml Dil-oxLDL was added, or 1.5ml of 10μg / ml Dil-oxLDL was added at the same time. 2 μg / ml, 5 μg / ml, 10 μg / ml, 20 μg / ml of sDSS1 protein. After continuing to incubate in the incubator for 5 hours, the intracellular fluorescent signal was observed with a fluorescence microscope, and the cells were digested with trypsin to form single cells for flow cytometry to detect the fluorescence intensity.

[0126] 2.2 Experimental results

[0127] After adding Dil-oxLDL to the HUVEC cell cultur...

Example Embodiment

[0128] Example 3. sDSS1 protein inhibits phagocytosis of oxLDL by macrophages.

[0129] 3.1 Experimental materials and methods

[0130] Experimental materials: sDSS1 protein, Dil-oxLDL, phorbol ester (PMA, Sigma-Aldrich, catalog number: P1585), human monocyte THP-1 (Cell Bank of the Chinese Academy of Sciences Type Culture Collection, catalog number: SCSP- 567).

[0131] Experimental method: THP-1 cells were seeded into 6-well plates according to the cell number of 250,000 per well, and the culture medium contained 100 ng / mL PMA. After the cells were activated by PMA for 48 hours, they were replaced with fresh medium and cultured for four days to help the cells to attach. Discard the old medium and add 1.5ml of 10μg / ml Dil-oxLDL, or add 1.5ml of 10μg / ml Dil-oxLDL simultaneously with sDSS1 protein at concentrations of 2μg / ml, 5μg / ml, 10μg / ml, 20μg / ml. After continuing to incubate in the incubator for 5 hours, the intracellular fluorescence signal was observed with a fluoresc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of protein in preparation of medicines for preventing and treating atherosclerosis and cardiovascular and cerebrovascular diseases and peripheral vascular diseases related to atherosclerosis. According to the invention, sDSS1 protein is used for preparing the medicines for preventing and treating the diseases. The sDSS1 protein can effectively reduce the level of oxidized low-density lipoprotein in animal blood of an atherosclerosis model, inhibit the ingestion of vascular endothelial cells and macrophages on oxidized low-density lipoprotein, can increase the intake of oxidized low-density lipoprotein by liver cells and reduce the area of atherosclerotic plaques in model group animals, and inhibit the progress of atherosclerosis or the progress of cardiovascular and cerebrovascular diseases and peripheral vascular diseases caused by atherosclerosis, which has great clinical application value.

Description

technical field [0001] The content of the invention belongs to the field of biomedicine, and relates to the application of a protein in the preparation of drugs for preventing and treating atherosclerosis and atherosclerosis complications. Background technique [0002] Atherosclerosis refers to the dysfunction of arteries due to the accumulation of lipids in the arterial wall to form lipid streaks or atheromatous plaques. The decrease of arterial vasomotor function, lumen stenosis and even thrombus due to plaque formation will affect the blood supply of tissues and organs supplied by the artery, resulting in partial or total ischemia of tissues and organs. [0003] Epidemiological data, preclinical research and clinical trial data from 1955 to the present show that dyslipidemia characterized by elevated low density lipoprotein cholesterol (LDL-c) is a key factor in atherosclerotic cardiovascular disease. Disease (atherosclerotic cardiovascular disease, ASCVD) important risk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P9/10
CPCA61K38/1709A61P9/10A61P25/28C07K14/4702A01K2227/105A01K2217/075A01K2267/0375A61K38/17C07K14/47C12N15/867
Inventor 张英豪王耀付晶鹏闫桂蕊
Owner SHANGHAI CLEAR FLUID BIOMEDICAL SCI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap